Monthly Prescribing Reference6d
Encapsulated Rapamycin Fast Tracked for Familial Adenomatous Polyposis
The Fast Track designation is supported by data from a phase 2 trial that evaluated eRapa in 30 adult patients with FAP.
Yahoo Finance3d
Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status
Biodexa, which has already received U.S. FDA Orphan Drug designation for eRapa in FAP, plans to seek a similar designation in Europe. eRapa is a proprietary oral tablet formulation of rapamycin ...